135 related articles for article (PubMed ID: 9434469)
21. Pathogenesis of diabetic neuropathy--do hyperglycemia and aldose reductase inhibitors affect neuroactive steroid formation in the rat sciatic nerves?
Colciago A; Negri-Cesi P; Celotti F
Exp Clin Endocrinol Diabetes; 2002 Jan; 110(1):22-6. PubMed ID: 11835121
[TBL] [Abstract][Full Text] [Related]
22. ["Diabetic autonomic neuropathy" series. Epidemiology, pathogenesis, basic therapy and prognosis].
Luft D
MMW Fortschr Med; 2002 May; 144(20):47-50. PubMed ID: 12119885
[No Abstract] [Full Text] [Related]
23. Medical therapy in the prevention of cataract.
Brown NA; Bron AJ
Trans Ophthalmol Soc U K (1962); 1985; 104 ( Pt 7)():748-54. PubMed ID: 3938085
[TBL] [Abstract][Full Text] [Related]
24. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
[TBL] [Abstract][Full Text] [Related]
25. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase.
Nakano T; Petrash JM
Biochemistry; 1996 Aug; 35(34):11196-202. PubMed ID: 8780524
[TBL] [Abstract][Full Text] [Related]
26. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
[TBL] [Abstract][Full Text] [Related]
27. The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus.
Roy TM; Broadstone VL; Peterson HR; Snider HL; Cyrus J; Fell R; Rothchild AH; Samols E; Pfeifer MA
Diabetes Res Clin Pract; 1990; 10(1):91-7. PubMed ID: 2123430
[TBL] [Abstract][Full Text] [Related]
28. Oxidized aldose reductase: in vivo factor not in vitro artifact.
Grimshaw CE; Lai CJ
Arch Biochem Biophys; 1996 Mar; 327(1):89-97. PubMed ID: 8615700
[TBL] [Abstract][Full Text] [Related]
29. Structural-functional interactions in the therapeutic response of diabetic neuropathy.
Sima AA; Greene DA
Diabet Med; 1993; 10 Suppl 2():33S-34S. PubMed ID: 8334838
[No Abstract] [Full Text] [Related]
30. Aldose reductase inhibitors and diabetic complications.
Tomlinson DR; Willars GB; Carrington AL
Pharmacol Ther; 1992; 54(2):151-94. PubMed ID: 1438531
[TBL] [Abstract][Full Text] [Related]
31. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study.
Datiles M; Fukui H; Kuwabara T; Kinoshita JH
Invest Ophthalmol Vis Sci; 1982 Feb; 22(2):174-9. PubMed ID: 6799419
[TBL] [Abstract][Full Text] [Related]
32. [Significance of aldose-reductase inhibition with traditional Chinese and Western drugs in the treatment of diabetic peripheral neuropathy].
Liang X; Guo S
Zhongguo Zhong Xi Yi Jie He Za Zhi; 1999 Jul; 19(7):442-4. PubMed ID: 11783220
[No Abstract] [Full Text] [Related]
33. Recent clinical experience with aldose reductase inhibitors.
Krans HM
J Diabetes Complications; 1992; 6(1):39-44. PubMed ID: 1562757
[TBL] [Abstract][Full Text] [Related]
34. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
Hotta N; Toyota T; Matsuoka K; Shigeta Y; Kikkawa R; Kaneko T; Takahashi A; Sugimura K; Koike Y; Ishii J; Sakamoto N;
Diabetes Care; 2001 Oct; 24(10):1776-82. PubMed ID: 11574441
[TBL] [Abstract][Full Text] [Related]
35. Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy.
Greene DA
J Diabetes Complications; 1992; 6(1):35-8. PubMed ID: 1562756
[TBL] [Abstract][Full Text] [Related]
36. Neurophysiological variables and fibrinolysis in insulin-dependent diabetes treated with an aldose reductase inhibitor or placebo. A double-blind randomized study.
Jespersen J; Gram J; Christensen JE
Haemostasis; 1986; 16(6):453-7. PubMed ID: 3108105
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of ranirestat for the treatment of diabetic neuropathy.
Giannoukakis N
Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):1051-9. PubMed ID: 24785785
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effect of orally administered aldose reductase inhibitor SNK-860 on corneal polyol accumulation in galactose-fed rats.
Kubo E; Nakamura S; Tsuzuki S; Takahashi Y; Akagi Y; Mizuno K; Matsubara A
Graefes Arch Clin Exp Ophthalmol; 1999 Sep; 237(9):758-62. PubMed ID: 10447652
[TBL] [Abstract][Full Text] [Related]
39. Aldose reductase inhibition and retinopathy.
Robison WG
Diabetes; 1994 Feb; 43(2):337-9. PubMed ID: 8288059
[No Abstract] [Full Text] [Related]
40. Treatment of diabetic neuropathy with inhibitors of the aldose reductase enzyme.
Green AJ; Jaspan JB
J Diabet Complications; 1990; 4(4):138-44. PubMed ID: 2151223
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
